NSI-189 Freebase

Description

NSI-189 Freebase

Buy NSI-189 Free Base Online

NSI-189 is an experimental small molecule developed for its potential effects on neurogenesis, cognition, and mood. It has attracted particular interest because its mechanism differs from conventional antidepressants that primarily target monoamine neurotransmitter systems.

Human clinical research has investigated NSI-189 phosphate in patients with major depressive disorder, while the free-base form is primarily encountered in research and commercial contexts.

Product Information

NSI-189 is a benzylpiperazine-aminopyridine derivative described as a neurogenic compound. Preclinical work has suggested effects involving hippocampal neurogenesis and neuronal function.

Importantly, the best-known human studies used NSI-189 phosphate, not necessarily the free-base material marketed by research suppliers. A phase 2 study evaluated 40 mg and 80 mg daily for 12 weeks.

How Does It Work?

NSI-189 is thought to influence neurogenic and neuroplastic processes rather than acting primarily as a serotonin, dopamine, or norepinephrine reuptake inhibitor. Its exact molecular mechanism remains incompletely defined.

Benefits

Strong Neurogenesis Research Interest

NSI-189 was developed around the concept of stimulating neurogenesis, particularly in the hippocampus. This makes it an unusual compound within the broader nootropic and neuropsychiatric research landscape.

Potential Cognitive Function Support

Preclinical studies have reported effects on cognitive and neuronal measures, while human trials have included cognitive and physical-functioning assessments.

Non-Monoaminergic Approach

Unlike conventional antidepressants that primarily manipulate monoamine signaling, NSI-189 was investigated as a neurogenic compound independent of monoamine reuptake pathways.

Investigated in Depression Research

NSI-189 has progressed beyond purely animal research. Human phase 1B and phase 2 studies evaluated its tolerability and potential effects in adults with major depressive disorder.

Side Effects

Clinical studies reported adverse events including headache, nausea, dizziness, gastrointestinal symptoms, fatigue, and changes in sleep or mood. Because the free-base formulation has not been as extensively studied clinically as the phosphate salt, formulation-specific safety remains uncertain.

Dosage

Human clinical research on NSI-189 phosphate evaluated 40 mg and 80 mg once daily for 12 weeks in a phase 2 depression trial. A phase 1B study also examined 40 mg once daily, 40 mg twice daily, and 40 mg three times daily.

These figures should not automatically be treated as an established dose for NSI-189 free base because the formulation and clinical context differ.

Where to Buy NSI-189 Free Base

Purerawz does not sell or directly supply NSI-189. Where available, affiliate links may direct readers to independent third-party providers.

References

1. Fava M, et al. A Phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder. Mol Psychiatry. 2019.
PubMed — PMID: 30626911
2. A Phase 1B study of NSI-189 phosphate in depressed patients.
PubMed — PMID: 26643541

Disclaimer

Purerawz does not sell, manufacture, stock, dispense, or directly supply any of the products discussed on this website. Purerawz is an independent information and affiliate platform. Where available, links may direct readers to independent third-party providers, and Purerawz may receive a commission from qualifying purchases at no additional cost to the reader.

The information is educational only.